Citi analyst John Deakin-Bell expects Nexstellis to become a positive contributor to earnings in fiscal 2023, and forecast peak sales of $US100 million the following year - about half of Mayne’s $US200 million target.As a result of FDA approval, Mayne Pharma will pay Mithra $11 million in cash and issue 85.8 million ordinary shares.
Citi analyst John Deakin-Bell expects Nexstellis to become a...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$5.25 |
Change
-0.150(2.78%) |
Mkt cap ! $426.5M | |||
| Open | High | Low | Value | Volume |
| $5.35 | $5.41 | $5.19 | $1.239M | 231.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $5.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.36 | 1000 | 1 |
View Market Depth
| Last trade - 16.11pm 25/07/2025 (20 minute delay) ? |
| MYX (ASX) Chart |